Intranasal administration of azilsartan (5 mg/kg for 45 days) demonstrated neuroprotective effects in an AlCl-induced Alzheimer's pathology animal model.
Does intranasal azilsartan provide neuroprotective effects in an AlCl3-induced animal model of Alzheimer's disease?
Intranasal azilsartan may offer neuroprotective effects in Alzheimer's pathology by targeting brain pathways directly.
Complex progressive neurodegenerative Alzheimer's disease is characterized by cognitive decline, memory impairment, and accumulation of amyloid and tau pathologies, along with aggravation of neuroinflammatory and oxidative stress pathways. In our previous studies, the potential of azilsartan, a widely used angiotensin receptor blocker (ARB), was demonstrated to possess neuroprotective action when administered through intranasal route, improving memory and cognition through modulation of central renin-angiotensin signalling in a demented animal model. With the intranasal administration, azilsartan nanoemulgel offers the ability to bypass the BBB due to the use of the olfactory and trigeminal neural pathways, achieving direct brain targeting of the therapeutics. In the present study, the neuroprotective effect of azilsartan (5 mg/kg via intranasal route consequently for 45 days) was further validated in an AlCl
Karmakar et al. (Fri,) conducted a other in Alzheimer's disease. Azilsartan was evaluated on Neuroprotective effect. Intranasal administration of azilsartan (5 mg/kg for 45 days) demonstrated neuroprotective effects in an AlCl-induced Alzheimer's pathology animal model.